AVXL News 0.3800 Anavex Life Sciences (AVXL)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anavex Life Sciences (AVXL) 0.3800 $AVXL

Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.

Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014.

Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.

Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.

Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014.

Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel.

Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.

Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's.

Anavex Agreement With The Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
GlobeNewswire - Tue Jan 14, 4:15PM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept(R)) for the treatment of Alzheimer's disease. This study will evaluate the safety, tolerability, pharmacokinetics, and possible clinical benefits of ANAVEX PLUS in Alzheimer's disease patients and other diseases associated with dementia and cognitive impairment.

Anavex CEO Invited to Present at Upcoming Investment Conferences
GlobeNewswire - Tue Jan 07, 7:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate in the 7 Annual OneMedForum: Investing in Healthcare 2014 ("OneMedForum" and the Noble Financial Capital Markets ("Noble" Tenth Annual Equity Conference.

Anavex Life Sciences Corp elects John Harrison to Scientific Advisory Board
M2 - Wed Dec 11, 4:18AM CST
Biopharmaceutical company Anavex Life Sciences Corp (OTC Markets:AVXL) revealed on Tuesday the election of John Harrison, PhD, to its Scientific Advisory Board.

Anavex Appoints Clinical Design Expert to Scientific Advisory Board
GlobeNewswire - Tue Dec 10, 7:10AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced the appointment of John Harrison, PhD, to its Scientific Advisory Board. Dr. Harrison is an internationally acknowledged specialist for design of human clinical outcome measurement in Alzheimer's disease and other cognitive impairments.

Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Anavex Life Sciences Corp hires Dr Michael Gold to Scientific Advisory Board
M2 - Wed Dec 04, 6:51AM CST
Biopharmaceutical company Anavex Life Sciences Corp (Other OTC:AVXL) revealed on Tuesday the election of Dr Michael Gold, MD as a member of its Scientific Advisory Board.

Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
PR Newswire - Tue Dec 03, 6:30AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board. Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company. His background also includes leadership roles with GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS).

Anavex Announces Expansion of Scientific Advisory Board
PR Newswire - Wed Nov 20, 6:30AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB: AVXL) announced today the appointment of Dr. Ottavio Arancio, MD, PhD to the Company's Scientific Advisory Board. Dr. Arancio is a cellular neurobiologist who has pioneered the field of mechanisms of synaptic dysfunction in Alzheimer's disease. He is Associate Professor of Pathology and Cell Biology at the Columbia University Medical Center and The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University. Over the last 10 years, Dr. Arancio has raised more than $25 million in grant funding and published more than 100 peer-reviewed scientific papers.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 181

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review Lawsuit Against Cepton, Inc. (CPTN)

Updated Category News Views 203

Class Action Against Cepton, Inc. Unveiled Recent developments have raised significant concerns for investors of Cepton, Inc. (NASDAQ: CPTN) following revelations of a class action lawsuit. Leading national plaintiffs' law firm Berger Montague has stepped in to help those impacted. The lawsuit focuses on investors who bought or sold Cepton shares during a specified...

Continue Reading
Exploring Uber Technologies: A Strategic Trade Perspective

Updated Category News Views 172

Uber Technologies Inc.'s Current Market Position Recently, ride-sharing giant Uber Technologies, Inc. (NYSE: UBER) experienced a notable increase in its market value. This uplift followed an innovative announcement regarding the capability for riders to book an Avride robotaxi, showcasing the evolution of autonomous mobility solutions. In the past five trading days, UBER...

Continue Reading
Celebrating Diversity: Winners of the Art Limitless Contest

Updated Category News Views 168

Celebrating the Art Limitless Competition Winners In the heart of artistic innovation, BE OPEN has unveiled the winners of the Art Limitless competition, an initiative celebrating inclusivity and diversity in the arts. This remarkable program strives to empower artists with disabilities, showcasing their work while inspiring broader societal awareness. What is Art...

Continue Reading
Certuity Welcomes Constantine Hatzivassiliou as New Partner

Updated Category News Views 246

Certuity Welcomes Constantine Hatzivassiliou as New Partner Certuity, a leading multi-family office dedicated to serving high-net-worth individuals and families, is thrilled to announce the promotion of Managing Director Constantine Hatzivassiliou to Partner. This significant advancement not only reflects Hatzivassiliou's commitment to the firm but also the invaluable...

Continue Reading
Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings

Updated Category News Views 124

Sila Realty Trust, Inc. Announces Upcoming Q3 Earnings Release Sila Realty Trust, Inc. (NYSE: SILA) recently made an announcement regarding its anticipated financial results for the third quarter of 2024. The company will release these earnings on a Tuesday morning, just before the market opens. This timely communication reflects Sila's commitment to transparency and...

Continue Reading